StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note published on Saturday morning. The firm issued a sell rating on the stock.

Separately, Dawson James began coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday, February 28th. They set a buy rating and a $3.00 price objective on the stock.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $0.18 on Friday. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $3.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. The business has a 50 day moving average of $0.27 and a 200 day moving average of $0.37. The company has a market capitalization of $15.16 million, a price-to-earnings ratio of -0.02 and a beta of 2.21.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million. On average, sell-side analysts predict that Tonix Pharmaceuticals will post -3.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,770,000 shares of the company’s stock after buying an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned about 14.09% of Tonix Pharmaceuticals worth $1,519,000 at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.